Physician profile
Terry M James
NPI 1225250640
$785.40
in general payments reported to CMS, 2019-2025
14 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.72 · 2020: $271 · 2021: $20.84 · 2022: $17.78 · 2023: $13.52 · 2024: $48.10 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $223.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $180.13 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $97.05 | 2020-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.84 | 2021-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $38.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.71 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $24.84 | 2020 | |
| Sunovion Pharmaceuticals INC. | $22.07 | 2020 | |
| Amgen INC. | $18.08 | 2020 | |
| Pfizer INC. | $17.60 | 2020 | |
| Lundbeck LLC | $16.35 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $15.26 | 2020 | |
| Merck Sharp & Dohme LLC | $14.31 | 2020 | |
| Boston Scientific Corporation | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.